NASDAQ:CRDF Cardiff Oncology Q3 2024 Earnings Report $2.10 +0.02 (+0.96%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$2.10 0.00 (-0.24%) As of 05:54 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast Cardiff Oncology EPS ResultsActual EPS-$0.25Consensus EPS -$0.27Beat/MissBeat by +$0.02One Year Ago EPSN/ACardiff Oncology Revenue ResultsActual Revenue$0.17 millionExpected Revenue$0.13 millionBeat/MissBeat by +$40.00 thousandYoY Revenue GrowthN/ACardiff Oncology Announcement DetailsQuarterQ3 2024Date11/7/2024TimeAfter Market ClosesConference Call DateThursday, November 7, 2024Conference Call Time4:00PM ETUpcoming EarningsCardiff Oncology's Q3 2025 earnings is scheduled for Thursday, November 6, 2025, with a conference call scheduled at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K) Cardiff Oncology Earnings HeadlinesBrokerages Set Cardiff Oncology, Inc. (NASDAQ:CRDF) Target Price at $10.10August 30 at 2:15 AM | americanbankingnews.comCardiff Oncology to Participate in Three Upcoming Investor ConferencesAugust 28, 2025 | globenewswire.comWashington prepares for warWhile the headlines obsess over overseas conflicts, Washington has been quietly preparing for something much bigger here at home. Emergency powers are being invoked, trillions are being mobilized, and the scale rivals anything we’ve seen since WWII. According to Porter Stansberry and Jeff Brown, a new economic arms race is already underway — one that could reshape markets, redirect capital, and impact billions of lives. They’ve just released an urgent briefing that explains what’s really happening behind the scenes, and which companies are positioned to benefit most. | Porter & Company (Ad)Cardiff Oncology, Inc. (NASDAQ:CRDF) Receives Average Rating of "Moderate Buy" from AnalystsAugust 27, 2025 | americanbankingnews.comCardiff Oncology Insiders Land Bargain With Gains Of US$244kJuly 31, 2025 | finance.yahoo.comCardiff Oncology Reports Second Quarter 2025 Results and Provides Business UpdateJuly 31, 2025 | finance.yahoo.comSee More Cardiff Oncology Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Cardiff Oncology? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cardiff Oncology and other key companies, straight to your email. Email Address About Cardiff OncologyCardiff Oncology (NASDAQ:CRDF), a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.View Cardiff Oncology ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles DICKS’s Sporting Goods Stock Dropped After Earnings—Is It a Buy?NVIDIA's Earnings Show a Green Light for Taiwan Semiconductor After Earnings Miss, Walmart Is Still a Top Consumer Staples PlayRoyal Caribbean Earnings Beat Fuels Strong 2025 OutlookDLocal Stock Soars 43% After Earnings Beat and Raised GuidanceGreen Dot's 30% Rally: Turnaround Takes Off on Explosive EarningsElbit Systems Jumps on Record Earnings and a $1.6B Contract Upcoming Earnings Salesforce (9/3/2025)Broadcom (9/4/2025)Oracle (9/8/2025)Synopsys (9/9/2025)Adobe (9/11/2025)FedEx (9/18/2025)Micron Technology (9/23/2025)AutoZone (9/23/2025)Cintas (9/24/2025)Costco Wholesale (9/25/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
